Mayne Pharma Group (STU:HG6) Buyback Yield % : 0.00 (As of Apr. 28, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Mayne Pharma Group Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Mayne Pharma Group's current buyback yield was 0.00%.

Mayne Pharma Group Buyback Yield % Historical Data

The historical data trend for Mayne Pharma Group's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Buyback Yield % Chart

Mayne Pharma Group Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Buyback Yield %

Get a 7-Day Free Trial

2.90

Mayne Pharma Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-	1.70	2.19	2.86	-

Competitive Comparison of Mayne Pharma Group's Buyback Yield %

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Mayne Pharma Group Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Mayne Pharma Group's Buyback Yield for the fiscal year that ended in Jun. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (-6.744	+	0)	/	232.36356
	=	2.90%

Mayne Pharma Group's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	0)		/	227.4888
	=	0.00%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Mayne Pharma Group Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (STU:HG6) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

MAYNF:USA MYX:Australia

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.

Mayne Pharma Group Headlines

No Headlines